NEWS | BEAM Alliance

NEWS

Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Basel, Switzerland, August 09, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 3 study with its antibiotic ceftobiprole. The registration study evaluates the safety and efficacy of ceftobiprole in the treatment of patients with bacteremia (bloodstream infections) caused by Staphylococcus aureus.

Full PR available here